Consensus Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Real-time Estimate Cboe BZX Other stock markets 01:37:28 2024-05-09 pm EDT			5-day change	1st Jan Change
8.19 ^USD	-2.27%		-0.37%	+25.69%

Apr. 30	RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	MT
Apr. 29	Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024

Evolution of the average Target Price on Avid Bioservices, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8ba2fd4194e5e6eacca95b90350.OpOAO40sVHq56tfCgXlJbovogBWw1AnI4vt56IvcYj0.cODlXsB7FU_c3aG7-TobWd2w8GH8v0CNq4g_vMCrBE8DyfJpuG06No24pA~d61a192b650f6237bee24d1efd6ad4bc

Analyst Recommendations on Avid Bioservices, Inc.

RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	Apr. 30	MT
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	Mar. 11	MT
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating	Dec. 08	MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating	Dec. 08	MT
RBC Cuts Price Target on Avid Bioservices to $7 From $15, Cites Slower Revenue Growth Assumptions Amid 'Challenging' Demand Backdrop; Outperform Kept	Dec. 08	MT
William Blair Initiates Coverage on Avid Bioservices with Market Perform Rating	23-09-28	MT
RBC Cuts Price Target on Avid Bioservices to $15 From $17 Amid 'Mixed' Fiscal Q1 Results, Keeps Outperform Rating	23-09-08	MT
Stephens Adjusts Avid Bioservices Price Target to $20 From $24, Maintains Overweight Rating	23-06-22	MT
Craig Hallum Adjusts Avid Bioservices Price Target to $22 From $25, Maintains Buy Rating	23-06-22	MT
RBC Cuts Price Target on Avid Bioservices to $17 From $20, Cites Softer-Than-Expected Revenue Guidance; Outperform Kept	23-06-22	MT
Avid Bioservices Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $20 After Fiscal Q3 Beat; Shares Up Pre-Bell	23-03-14	MT
RBC Cuts Price Target on Avid Bioservices to $20 From $22, Notes Fiscal Q2 Adjusted EBITDA Miss, Keeps Outperform Rating	22-12-07	MT
RBC Cuts Price Target on Avid Bioservices to $22 From $32, Citing Lower Group Multiples, Maintains Outperform Rating	22-06-30	MT
Craig-Hallum Lowers Price Target for Avid Bioservices to $30 From $35, Maintains Buy Rating	22-03-09	MT
Stephens Adjusts Avid Bioservices' Price Target to $28 from $31, Keeps Overweight Rating	22-03-09	MT
Craig-Hallum Adjusts Price Target on Avid Bioservices to $35 From $29, Keeps Buy Rating	21-12-08	MT
RBC Lifts Price Target on Avid Bioservices to $32 From $27, Calls Fiscal Q2 'Impressive Quarter for New Business Wins,' Keeps Outperform	21-12-08	MT
KeyBanc Downgrades Avid Bioservices to Sector Weight From Overweight	21-12-08	MT
AVID BIOSERVICES : Craig-Hallum Adjusts Price Target on Avid Bioservices to $29 From $21, Maintains Buy Rating	21-06-30	MT
AVID BIOSERVICES : KeyBanc Adjusts Avid Bioservices' Price Target to $28 From $22, Reiterates Overweight Rating	21-06-30	MT
AVID BIOSERVICES : RBC Raises Price Target on Avid Bioservices to $27 From $21 After Fiscal Q4 Revenue Beat, Maintains Outperform Rating	21-06-30	MT
AVID BIOSERVICES : Initiated at Outperform by RBC, Price Target Set at $21	21-03-17	MT
AVID BIOSERVICES : KeyBanc Initiates Avid Bioservices at Overweight with $12 Price Target	20-11-10	MT